NEW YORK, April 4 /PRNewswire-FirstCall/ -- Dr. Joshua Schein, Chief Executive Officer of Lev Pharmaceuticals, Inc. , will present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference at The Millennium Broadway Hotel in New York, NY on Wednesday, April 11, 2007.
The Lev Pharmaceuticals presentation is scheduled to begin at 4:15 PM. It will be accessible via webcast by clicking on the link below: http://www.veracast.com/webcasts/cibcwm/biotech07/08114355.cfm. The above link can be used for both the live and archived webcast. The webcast will automatically be archived approximately three hours after the live event and will be available for 90 days through July 11, 2007. For information about the CIBC Annual Biotechnology & Specialty Pharmaceuticals conference, please visit: http://conferences.cibcwm.com/biotech07/ or call (212) 667-7135.
ABOUT LEV PHARMACEUTICALS
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The Company recently announced successful Phase III Clinical CHANGE (C1-inhibitor in Hereditary Angioedema Nano filtration Generation evaluating Efficacy) Trial results of its lead product, C1-INH-nf (C1-INH nano- filtration), for the acute treatment of Hereditary Angioedema (HAE). In addition, Lev is currently conducting a registrational Phase III clinical trial for the prophylactic treatment of HAE. Based on the positive results of the CHANGE study, the Company intends to submit a Biologics License Application to the Food and Drug Administration in the second quarter of 2007. Lev is also evaluating the development of C1-INH-nf for the treatment of cardiovascular disease and other diseases and disorders in which inflammation is known or believed to play an underlying role, including, but not limited to, myocardial infarction (heart attack). Lev's C1-INH-nf has been granted orphan drug status for the treatment of HAE by the FDA, potentially securing, upon approval, market exclusivity for seven years.
The company's principal Web site is http://www.levpharma.com. Corporate headquarters are located at 675 3rd Ave., Suite 2200 New York, NY 10017.
Lev Pharmaceuticals, Inc.CONTACT: Jeff Siegel of Monarch Communications, +1-516-569-4271, for LevPharmaceuticals, Inc.
